Phase II Study on NIVolumab in combination with FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan)/Bevacizumab in first line chemotherapy of Advanced COloRectal cancer patients with mutated RAS or BRAF genes.

ABSTRACT: Primary objectives: Evaluate the activity of Nivolumab in combination with FOLFOXIRI and bevacizumab. Primary endpoints: To demonstrate that adding nivolumab to standard colorectal first line chemotherapy improves the Overall Response Rate as determinated by investigators using RECIST 1.1 criteria.

DISEASE(S): Carcinoma Colorettale Avanzato,Colorectal Cancer Metastatic,Advanced Colorectal Cancer,Advanced Colorectal Cancer

PROVIDER: 2538383 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR